These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1165 related items for PubMed ID: 28086180

  • 1. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E, Lee EJ, Nam GH, Hong Y, Cho E, Yang Y, Kim IS.
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, Doyle LV, Kauder SE, Fontaine D, Bollini S, Han B, Fu YX, Sim J, Pons J, Wan HI.
    J Hematol Oncol; 2020 Nov 30; 13(1):160. PubMed ID: 33256806
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K.
    Eur J Cancer; 2017 May 30; 76():100-109. PubMed ID: 28286286
    [Abstract] [Full Text] [Related]

  • 7. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K.
    Cancer Immunol Immunother; 2022 Feb 30; 71(2):473-489. PubMed ID: 34247273
    [Abstract] [Full Text] [Related]

  • 8. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S, Ni T, Wang J, Liu Y, Fan Q, Wang Y, Huang T, Chu Y, Sun X, Wang Y.
    J Immunol Res; 2018 Feb 30; 2018():6156757. PubMed ID: 30525058
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
    Lv Z, Bian Z, Shi L, Niu S, Ha B, Tremblay A, Li L, Zhang X, Paluszynski J, Liu M, Zen K, Liu Y.
    J Immunol; 2015 Jul 15; 195(2):661-71. PubMed ID: 26085683
    [Abstract] [Full Text] [Related]

  • 13. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R.
    Clin Cancer Res; 2016 Oct 15; 22(20):5109-5119. PubMed ID: 27126995
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, Kawamoto K, Yanagida E, Yamada K, Umeno T, Suzuki T, Kato K, Takizawa J, Seto M, Akashi K, Ohshima K.
    Cancer Sci; 2020 Jul 15; 111(7):2608-2619. PubMed ID: 32342603
    [Abstract] [Full Text] [Related]

  • 16. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H, Zhao H, Xu J, Evans CE, Jin H.
    Front Immunol; 2020 Jul 15; 11():18. PubMed ID: 32082311
    [Abstract] [Full Text] [Related]

  • 17. Comparison of exosomes and ferritin protein nanocages for the delivery of membrane protein therapeutics.
    Cho E, Nam GH, Hong Y, Kim YK, Kim DH, Yang Y, Kim IS.
    J Control Release; 2018 Jun 10; 279():326-335. PubMed ID: 29679665
    [Abstract] [Full Text] [Related]

  • 18. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X, Yan B, Tian X, Liu Q, Jin J, Shi J, Hou Y.
    Int J Biol Sci; 2021 Jun 10; 17(13):3281-3287. PubMed ID: 34512146
    [Abstract] [Full Text] [Related]

  • 19. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A, Van der Burg SH, Scheeren FA.
    J Immunother Cancer; 2022 Jul 10; 10(7):. PubMed ID: 35831032
    [Abstract] [Full Text] [Related]

  • 20. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.
    Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, Hazama D, Washio K, Saito Y, Kotani T, Ohnishi H, Oldenborg PA, Garcia NV, Miyasaka M, Ishikawa O, Kanai Y, Komori T, Matozaki T.
    JCI Insight; 2017 Jan 12; 2(1):e89140. PubMed ID: 28097229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.